Centre to cap trade margins on non-scheduled cancer drugs to 30% of MRP
The Indian government will limit trade margins on non‑scheduled cancer drugs to 30 % of the maximum retail price. Currently, the average markup is about 170 %, with some drugs reaching 700 %. The new cap could reduce prices by up to 70 % of the MRP, yielding roughly ₹2,500 crore in yearly savings for all patients in India.